Patents by Inventor Mark T. Bilodeau

Mark T. Bilodeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tyrosine kinase inhibitors
    Publication number: 20040235867
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: January 23, 2004
    Publication date: November 25, 2004
    Inventors: Mark T. Bilodeau, Peter J. Manley, George D. Hartman
  • Tyrosine kinase inhibitors
    Publication number: 20040220201
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: January 29, 2004
    Publication date: November 4, 2004
    Inventors: Mark T. Bilodeau, Peter J. Manley, Adrienne Balitza, George D. Hartman, Leonard Rodman
  • Tyrosine kinase inhibitors
    Patent number: 6794393
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 21, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Tyrosine kinase inhibitors
    Publication number: 20040063720
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 1, 2004
    Applicant: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
  • Active salt forms with tyrosine kinase activity
    Publication number: 20040023978
    Abstract: The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: June 26, 2003
    Publication date: February 5, 2004
    Inventors: Yu Ren, Shyam B. Karki, Matthew M. Zhao, Mark T. Bilodeau
  • Polymorphs with tyrosine kinase activity
    Publication number: 20040023980
    Abstract: The present invention relates to active polymorphs of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: June 26, 2003
    Publication date: February 5, 2004
    Inventors: Matthew M. Zhao, Mark T. Bilodeau
  • Tyrosine kinase inhibitors
    Patent number: 6586423
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley, Randall W. Hungate, Leonard Rodman
  • Tyrosine kinase inhibitors
    Patent number: 6586424
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
  • Tyrosine kinase inhibitors
    Publication number: 20030100567
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: June 19, 2002
    Publication date: May 29, 2003
    Inventors: Mark T. Bilodeau, George D. Hartman
  • Tyrosine kinase inhibitors
    Patent number: 6544988
    Abstract: The present invention relates to pyrazolo-pyrimidinyl compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: April 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate
  • Tyrosine kinase inhibitors
    Publication number: 20030064996
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 1, 2002
    Publication date: April 3, 2003
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley, Randall W. Hungate, Leonard Rodman
  • Angiogenesis inhibitors
    Patent number: 6465484
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tryrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Randall W. Hungate, April M. Cunningham, Timothy J. Koester
  • Tyrosine kinase inhibitors
    Publication number: 20020147203
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 1, 2002
    Publication date: October 10, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Peter J. Manley
  • Tyrosine kinase inhibitors
    Publication number: 20020137755
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: November 21, 2001
    Publication date: September 26, 2002
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
  • Angiogenesis inhibitors
    Patent number: 6380203
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate, Richard L. Kendall, Ruth Rutledge, Kenneth A. Thomas, Jr., Robert Rubino
  • Tyrosine kinase inhibitors
    Patent number: 6306874
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: October 23, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Tyrosine kinase inhibitors
    Patent number: 6245759
    Abstract: The present invention relates to pyrazolo-pyrimidinyl compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: June 12, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Fraley, Randall W. Hungate
  • Angiogenesis inhibitors
    Patent number: 6235741
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: May 22, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Randall W. Hungate, Richard L. Kendall, Ruth Rutledge, Kenneth A. Thomas, Jr., Robert Rubino, Mark E. Fraley
  • Tyrosine kinase inhibitors
    Patent number: 6162804
    Abstract: The present invention relates to benzinidazole compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: December 19, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, April M. Cunningham, Randall W. Hungate, Timothy J. Koester
  • Synthesis of the breast tumor-associated antigen defined by monoclonal antibody MBr1 and uses thereof
    Patent number: 6090789
    Abstract: The present invention provides a process for synthesizing a compound having the structure: ##STR1## wherein R is H, as well as related oligosaccharides useful as a vaccine for inducing antibodies to human breast cancer cells in an adjuvant therapy therefor.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: July 18, 2000
    Assignee: Sloan-Kettering Institute For Cancer Research
    Inventors: Samuel J. Danishefsky, Mark T. Bilodeau, Shuang Hua Hu, Tae Kyo Park, John T. Randolph, In Jong Kim, Philip O. Livingston